BD Veritor™:
The right outcome
begins with the right test

Integrated, digitally connected testing that removes any guesswork—by interpreting and providing rapid, clear results for SARS-CoV-2, Flu A+B, Flu A+B & SARS-CoV-2,* Group A Strep, and RSV—so you can move forward with confidence.

 

Get Support

 

Homepage Banner
Content Card Image

Save on rapid antigen tests!

Buy 4 kits, get 1 at no additional cost

Content Card Image

COVID-19 seasonal savings

Now 510k Cleared

Content Card Image

Get a no cost analyzer

Buy 2 kits, get 1 Analyzer at NO COST!

Where to Buy

Contact a Sales Representative to get your organization’s

diagnostic testing program started today

RSV=respiratory syncytial virus; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.

*In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID 19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.